Negative regulation of NF-κB and its involvement in rheumatoid arthritis

Arthritis Research and Therapy

Volumn 13, Issue 3, 2011, Pages

  van Loo, Geert ^a,b   Beyaert, Rudi ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

A20 PROTEIN; ABIN 1 PROTEIN; ABIN 2 PROTEIN; ABIN 3 PROTEIN; B CELL ACTIVATING FACTOR; CD40 ANTIGEN; CYCLOOXYGENASE 1; CYLINDROMATOSIS PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 6; LYMPHOTOXIN BETA RECEPTOR; MESSENGER RNA; MICRORNA; OLIGONUCLEOTIDE; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN; PROTEIN P100; PROTEIN P105; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RITUXIMAB; SINGLE IMMUNOGLOBULIN INTERLEUKIN 1 RECEPTOR RELATED PROTEIN; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; UNCLASSIFIED DRUG;

CD4+ T LYMPHOCYTE; FIBROBLAST; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; MICROARRAY ANALYSIS; NEGATIVE FEEDBACK; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOLYSIS; PATHOGENESIS; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; RNA DEGRADATION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYNOVIOCYTE; TH1 CELL; TH17 CELL; ANIMAL; GENETIC TRANSCRIPTION; GENETICS; IMMUNOLOGY; METABOLISM;

ANIMALS; ARTHRITIS, RHEUMATOID; HUMANS; NF-KAPPA B; TRANSCRIPTION, GENETIC;

EID: 82455162312     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3324     Document Type: Review

References (91)

1. Hayden MS, Ghosh S. Shared principles in NF-κB signaling. Cell 2008, 132:344-362. 10.1016/j.cell.2008.01.020, 18267068.
2. Simmonds RE, Foxwell BM. Signalling, inflammation and arthritis: NF-κB and its relevance to arthritis and inflammation. Rheumatology (Oxford) 2008, 47:584-590.
3. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008, 118:3537-3545. 10.1172/JCI36389, 2575731, 18982160.
4. Roman-Blas JA, Jimenez SA. Targeting NF-κB: a promising molecular therapy in inflammatory arthritis. Int Rev Immunol 2008, 27:351-374. 10.1080/08830180802295740, 18853343.
5. Han Z, Boyle DL, Manning AM, Firestein GS. AP-1 and NF-κB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 1998, 28:197-208. 10.3109/08916939808995367, 9892501.
6. Keith JC, Albert LM, Leathurby Y, Follettie M, Wang L, Borges-Marcucci L, Chadwick CC, Steff an RJ, Harnish DC. The utility of pathway selective estrogen receptor ligands that inhibit nuclear factor-kappa B transcriptional activity in models of rheumatoid arthritis. Arthritis Res Ther 2005, 7:R427-R438. 10.1186/ar1692, 1174937, 15899029.
7. Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 2006, 12:17-25. 10.1016/j.molmed.2005.11.007, 16356770.
8. Criswell LA. Gene discovery in rheumatoid arthritis highlights the CD40/NF-κB signaling pathway in disease pathogenesis. Immunol Rev 2010, 233:55-61. 10.1111/j.0105-2896.2009.00862.x, 20192992.
9. Taylor PC, Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 2009, 5:578-582. 10.1038/nrrheum.2009.181, 19798034.
10. Rissoan MC, Van Kooten C, Chomarat P, Galibert L, Durand I, Thivolet-Bejui F, Miossec P, Banchereau J. The functional CD40 antigen of fi broblasts may contribute to the proliferation of rheumatoid synovium. Clin Exp Immunol 1996, 106:481-490. 10.1046/j.1365-2249.1996.d01-858.x, 2200616, 8973616.
11. Durie FH, Fava RA, Foy TM, Aruff o A, Ledbetter JA, Noelle RJ. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 1993, 261:1328-1330. 10.1126/science.7689748, 7689748.
12. Kyburz D, Carson DA, Corr M. The role of CD40 ligand and tumor necrosis factor alpha signaling in the transgenic K/BxN mouse model of rheumatoid arthritis. Arthritis Rheum 2000, 43:2571-2577. 10.1002/1529-0131(200011)43:11<2571::AID-ANR26>3.0.CO;2-4, 11083282.
13. Brown KD, Claudio E, Siebenlist U. The roles of the classical and alternative nuclear factor-κB pathways: potential implications for autoimmunity and rheumatoid arthritis. Arthritis Res Ther 2008, 10:212. 10.1186/ar2457, 2575629, 18771589.
14. Huang QQ, Pope RM. The role of toll-like receptors in rheumatoid arthritis. Curr Rheumatol Rep 2009, 11:357-364. 10.1007/s11926-009-0051-z, 2913446, 19772831.
15. Yu L, Wang L, Chen S. Endogenous toll-like receptor ligands and their biological significance. J Cell Mol Med 2010, 14:2592-2603. 10.1111/j.1582-4934.2010.01127.x, 20629986.
16. Kokkola R, Li J, Sundberg E, Aveberger AC, Palmblad K, Yang H, Tracey KJ, Andersson U, Harris HE. Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum 2003, 48:2052-2058. 10.1002/art.11161, 12847700.
17. Frosch M, Strey A, Vogl T, Wulff raat NM, Kuis W, Sunderkotter C, Harms E, Sorg C, Roth J. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 2000, 43:628-637. 10.1002/1529-0131(200003)43:3<628::AID-ANR20>3.0.CO;2-X, 10728757.
18. Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, Nacken W, Foell D, van der Poll T, Sorg C, Roth J. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007, 13:1042-1049. 10.1038/nm1638, 17767165.
19. Vallabhapurapu S, Karin M. Regulation and function of NF-κB transcription factors in the immune system. Annu Rev Immunol 2009, 27:693-733. 10.1146/annurev.immunol.021908.132641, 19302050.
20. Liu S, Chen ZJ. Expanding role of ubiquitination in NF-κB signaling. Cell Res 2011, 21:6-21. 10.1038/cr.2010.170, 21135871.
21. Pasparakis M, Luedde T, Schmidt-Supprian M. Dissection of the NF-κB signalling cascade in transgenic and knockout mice. Cell Death Differ 2006, 13:861-872. 10.1038/sj.cdd.4401870, 16470223.
22. Tokunaga F, Sakata S, Saeki Y, Satomi Y, Kirisako T, Kamei K, Nakagawa T, Kato M, Murata S, Yamaoka S, Yamamoto M, Akira S, Takao T, Tanaka K, Iwai K. Involvement of linear polyubiquitylation of NEMO in NF-κB activation. Nat Cell Biol 2009, 11:123-132. 10.1038/ncb1821, 19136968.
23. Xia ZP, Sun L, Chen X, Pineda G, Jiang X, Adhikari A, Zeng W, Chen ZJ. Direct activation of protein kinases by unanchored polyubiquitin chains. Nature 2009, 461:114-119. 10.1038/nature08247, 2747300, 19675569.
24. Kawagoe T, Sato S, Matsushita K, Kato H, Matsui K, Kumagai Y, Saitoh T, Kawai T, Takeuchi O, Akira S. Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2. Nat Immunol 2008, 9:684-691. 10.1038/ni.1606, 18438411.
25. Hacker H, Redecke V, Blagoev B, Kratchmarova I, Hsu LC, Wang GG, Kamps MP, Raz E, Wagner H, Hacker G, Mann M, Karin M. Specificity in Toll-like receptor signalling through distinct eff ector functions of TRAF3 and TRAF6. Nature 2006, 439:204-207. 10.1038/nature04369, 16306937.
26. Cusson-Hermance N, Khurana S, Lee TH, Fitzgerald KA, Kelliher MA. Rip1 mediates the Trif-dependent toll-like receptor 3- and 4-induced NF-κB activation but does not contribute to interferon regulatory factor 3 activation. J Biol Chem 2005, 280:36560-36566. 10.1074/jbc.M506831200, 16115877.
27. Sun SC. Non-canonical NF-κB signaling pathway. Cell Res 2011, 21:71-85. 10.1038/cr.2010.177, 21173796.
28. Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G, Chen Y, Hu Y, Fong A, Sun SC, Karin M. Activation by IKKα of a second, evolutionary conserved, NF-κB signaling pathway. Science 2001, 293:1495-1499. 10.1126/science.1062677, 11520989.
29. Xiao G, Fong A, Sun SC. Induction of p100 processing by NF-κB-inducing kinase involves docking IκB kinase alpha (IKKα) to p100 and IKKα- mediated phosphorylation. J Biol Chem 2004, 279:30099-30105. 10.1074/jbc.M401428200, 15140882.
30. Peters AL, Bishop GA. Differential TRAF3 utilization by a variant human CD40 receptor with enhanced signaling. J Immunol 2010, 185:6555-6562. 10.4049/jimmunol.1000135, 21041727.
31. Sanjo H, Zajonc DM, Braden R, Norris PS, Ware CF. Allosteric regulation of the ubiquitin:NIK and ubiquitin:TRAF3 E3 ligases by the lymphotoxin-beta receptor. J Biol Chem 2010, 285:17148-17155. 10.1074/jbc.M110.105874, 2878066, 20348096.
32. Renner F, Schmitz ML. Autoregulatory feedback loops terminating the NF-κB response. Trends Biochem Sci 2009, 34:128-135. 10.1016/j.tibs.2008.12.003, 19233657.
33. Liew FY, Xu D, Brint EK, O'Neill LA. Negative regulation of toll-like receptormediated immune responses. Nat Rev Immunol 2005, 5:446-458. 10.1038/nri1630, 15928677.
34. Lawrence T, Bebien M, Liu GY, Nizet V, Karin M. IKKα limits macrophage NF-κB activation and contributes to the resolution of inflammation. Nature 2005, 434:1138-1143. 10.1038/nature03491, 15858576.
35. Liu B, Yang Y, Chernishof V, Loo RR, Jang H, Tahk S, Yang R, Mink S, Shultz D, Bellone CJ, Loo JA, Shuai K. Proinflammatory stimuli induce IKKα-mediated phosphorylation of PIAS1 to restrict inflammation and immunity. Cell 2007, 129:903-914. 10.1016/j.cell.2007.03.056, 17540171.
36. Razani B, Zarnegar B, Ytterberg AJ, Shiba T, Dempsey PW, Ware CF, Loo JA, Cheng G. Negative feedback in noncanonical NF-κB signaling modulates NIK stability through IKKα-mediated phosphorylation. Sci Signal 2010, 3:ra41. 10.1126/scisignal.2000778, 2913610, 20501937.
37. Coornaert B, Carpentier I, Beyaert R. A20: central gatekeeper in inflammation and immunity. J Biol Chem 2009, 284:8217-8221. 2659177, 19008218.
38. Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, Wu P, Wiesmann C, Baker R, Boone DL, Ma A, Koonin EV, Dixit VM. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling. Nature 2004, 430:694-699. 10.1038/nature02794, 15258597.
39. Hitotsumatsu O, Ahmad RC, Tavares R, Wang M, Philpott D, Turer EE, Lee BL, Shiffin N, Advincula R, Malynn BA, Werts C, Ma A. The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals. Immunity 2008, 28:381-390. 10.1016/j.immuni.2008.02.002, 18342009.
40. Boone DL, Turer EE, Lee EG, Ahmad RC, Wheeler MT, Tsui C, Hurley P, Chien M, Chai S, Hitotsumatsu O, McNally E, Pickart C, Ma A. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 2004, 5:1052-1060. 10.1038/ni1110, 15334086.
41. Duwel M, Welteke V, Oeckinghaus A, Baens M, Kloo B, Ferch U, Darnay BG, Ruland J, Marynen P, Krappmann D. A20 negatively regulates T cell receptor signaling to NF-κB by cleaving Malt1 ubiquitin chains. J Immunol 2009, 182:7718-7728. 10.4049/jimmunol.0803313, 19494296.
42. Shembade N, Ma A, Harhaj EW. Inhibition of NF-κB signaling by A20 through disruption of ubiquitin enzyme complexes. Science 2010, 327:1135-1139. 10.1126/science.1182364, 3025292, 20185725.
43. Iha H, Peloponese JM, Verstrepen L, Zapart G, Ikeda F, Smith CD, Starost MF, Yedavalli V, Heyninck K, Dikic I, Beyaert R, Jeang KT. Inflammatory cardiac valvulitis in TAX1BP1-deficient mice through selective NF-κB activation. EMBO J 2008, 27:629-641. 10.1038/emboj.2008.5, 2262037, 18239685.
44. Wagner S, Carpentier I, Rogov V, Kreike M, Ikeda F, Lohr F, Wu CJ, Ashwell JD, Dotsch V, Dikic I, Beyaert R. Ubiquitin binding mediates the NF-κB inhibitory potential of ABIN proteins. Oncogene 2008, 27:3739-3745. 10.1038/sj.onc.1211042, 18212736.
45. Shembade N, Harhaj NS, Liebl DJ, Harhaj EW. Essential role for TAX1BP1 in the termination of TNF-α-, IL-1- and LPS-mediated NF-κB and JNK signaling. EMBO J 2007, 26:3910-3922. 10.1038/sj.emboj.7601823, 1994124, 17703191.
46. Lee EG, Boone DL, Chai S, Libby SL, Chien M, Lodolce JP, Ma A. Failure to regulate TNF-induced NF-κB and cell death responses in A20-deficient mice. Science 2000, 289:2350-2354. 10.1126/science.289.5488.2350, 11009421.
47. Vereecke L, Sze M, Guire CM, Rogiers B, Chu Y, Schmidt-Supprian M, Pasparakis M, Beyaert R, van Loo G. Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis. J Exp Med 2010, 207:1513-1523. 10.1084/jem.20092474, 2901067, 20530205.
48. Tavares RM, Turer EE, Liu CL, Advincula R, Scapini P, Rhee L, Barrera J, Lowell CA, Utz PJ, Malynn BA, Ma A. The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity. Immunity 2010, 33:181-191. 10.1016/j.immuni.2010.07.017, 20705491.
49. Chu Y, Vahl JC, Kumar D, Heger K, Bertossi A, Wojtowicz E, Soberon V, Schenten D, Mack B, Reutelshofer M, Beyaert R, Amann K, van Loo G, Schmidt-Supprian M. B cells lacking the tumor suppressor TNFAIP3/A20 display impaired differentiation and hyperactivation and cause inflammation and autoimmunity in aged mice. Blood 2011, 117:2227-2236. 10.1182/blood-2010-09-306019, 21088135.
50. Krikos A, Laherty CD, Dixit VM. Transcriptional activation of the tumor necrosis factor alpha-inducible zinc finger protein, A20, is mediated by kappa B elements. J Biol Chem 1992, 267:17971-17976.
51. Hah YS, Lee YR, Jun JS, Lim HS, Kim HO, Jeong YG, Hur GM, Lee SY, Chung MJ, Park JW, Lee SI, Park BH. A20 suppresses inflammatory responses and bone destruction in human fibroblast-like synoviocytes and in mice with collagen-induced arthritis. Arthritis Rheum 2010, 62:2313-2321. 10.1002/art.27545, 20506221.
52. Vereecke L, Beyaert R, van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol 2009, 30:383-391. 10.1016/j.it.2009.05.007, 19643665.
53. Elsby LM, Orozco G, Denton J, Worthington J, Ray DW, Donn RP. Functional evaluation of TNFAIP3 (A20) in rheumatoid arthritis. Clin Exp Rheumatol 2010, 28:708-714. 3093652, 20822710.
54. Verstrepen L, Carpentier I, Verhelst K, Beyaert R. ABINs: A20 binding inhibitors of NF-kappa B and apoptosis signaling. Biochem Pharmacol 2009, 78:105-114. 10.1016/j.bcp.2009.02.009, 19464428.
55. Papoutsopoulou S, Symons A, Tharmalingham T, Belich MP, Kaiser F, Kioussis D, O'Garra A, Tybulewicz V, Ley SC. ABIN-2 is required for optimal activation of Erk MAP kinase in innate immune responses. Nat Immunol 2006, 7:606-615.
56. Oshima S, Turer EE, Callahan JA, Chai S, Advincula R, Barrera J, Shifrin N, Lee B, Benedict Yen TS, Woo T, Malynn BA, Ma A. ABIN-1 is a ubiquitin sensor that restricts cell death and sustains embryonic development. Nature 2009, 457:906-909. 10.1038/nature07575, 2642523, 19060883.
57. Wullaert A, Verstrepen L, Van Huff el S, Adib-Conquy M, Cornelis S, Kreike M, Haegman M, El Bakkouri K, Sanders M, Verhelst K, Carpentier I, Cavaillon JM, Heyninck K, Beyaert R. LIND/ABIN-3 is a novel lipopolysaccharide-inducible inhibitor of NF-κB activation. J Biol Chem 2007, 282:81-90.
58. Wullaert A, Wielockx B, Van Huff el S, Bogaert V, De Geest B, Papeleu P, Schotte P, El Bakkouri K, Heyninck K, Libert C, Beyaert R. Adenoviral gene transfer of ABIN-1 protects mice from TNF/galactosamine-induced acute liver failure and lethality. Hepatology 2005, 42:381-389. 10.1002/hep.20785, 16025521.
59. Gallagher J, Howlin J, McCarthy C, Murphy EP, Bresnihan B, FitzGerald O, Godson C, Brady HR, Martin F. Identification of Naf1/ABIN-1 among TNF-α- induced expressed genes in human synoviocytes using oligonucleotide microarrays. FEBS Lett 2003, 551:8-12. 10.1016/S0014-5793(03)00823-8, 12965196.
60. Wang L, Gordon RA, Huynh L, Su X, Park Min KH, Han J, Arthur JS, Kalliolias GD, Ivashkiv LB. Indirect inhibition of Toll-like receptor and type I interferon responses by ITAM-coupled receptors and integrins. Immunity 2010, 32:518-530. 10.1016/j.immuni.2010.03.014, 2862476, 20362473.
61. Nair RP, Duffi n KC, Helms C, Ding J, Stuart PE, Goldgar D, Gudjonsson JE, Li Y, Tejasvi T, Feng BJ, Ruether A, Schreiber S, Weichenthal M, Gladman D, Rahman P, Schrodi SJ, Prahalad S, Guthery SL, Fischer J, Liao W, Kwok PY, Menter A, Lathrop GM, Wise CA, Begovich AB, Voorhees JJ, Elder JT, Krueger GG, Bowcock AM, Abecasis GR. Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways. Nat Genet 2009, 41:199-204. 10.1038/ng.311, 2745122, 19169254.
62. Gateva V, Sandling JK, Hom G, Taylor KE, Chung SA, Sun X, Ortmann W, Kosoy R, Ferreira RC, Nordmark G, Gunnarsson I, Svenungsson E, Padyukov L, Sturfelt G, Jonsen A, Bengtsson AA, Rantapaa-Dahlqvist S, Baechler EC, Brown EE, Alarcon GS, Edberg JC, Ramsey-Goldman R, McGwin G, Reveille JD, Vila LM, Kimberly RP, Manzi S, Petri MA, Lee A, Gregersen PK, et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet 2009, 41:1228-1233. 10.1038/ng.468, 2925843, 19838195.
63. Bignell GR, Warren W, Seal S, Takahashi M, Rapley E, Barfoot R, Green H, Brown C, Biggs PJ, Lakhani SR, Jones C, Hansen J, Blair E, Hofmann B, Siebert R, Turner G, Evans DG, Schrander-Stumpel C, Beemer FA, van Den Ouweland A, Halley D, Delpech B, Cleveland MG, Leigh I, Leisti J, Rasmussen S. Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet 2000, 25:160-165. 10.1038/76006, 10835629.
64. Sun SC. CYLD: a tumor suppressor deubiquitinase regulating NF-κB activation and diverse biological processes. Cell Death Differ 2010, 17:25-34. 10.1038/cdd.2009.43, 19373246.
65. Jin W, Chang M, Paul EM, Babu G, Lee AJ, Reiley W, Wright A, Zhang M, You J, Sun SC. Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice. J Clin Invest 2008, 118:1858-1866. 10.1172/JCI34257, 2276399, 18382763.
66. Kurihara N, Hiruma Y, Zhou H, Subler MA, Dempster DW, Singer FR, Reddy SV, Gruber HE, Windle JJ, Roodman GD. Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease. J Clin Invest 2007, 117:133-142. 10.1172/JCI28267, 1705822, 17187080.
67. Wald D, Qin J, Zhao Z, Qian Y, Naramura M, Tian L, Towne J, Sims JE, Stark GR, Li X. SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol 2003, 4:920-927. 10.1038/ni968, 12925853.
68. McCormack WJ, Parker AE, O'Neill LA. Toll-like receptors and NOD-like receptors in rheumatic diseases. Arthritis Res Ther 2009, 11:243. 10.1186/ar2729, 2787278, 19835640.
69. Polentarutti N, Rol GP, Muzio M, Bosisio D, Camnasio M, Riva F, Zoja C, Benigni A, Tomasoni S, Vecchi A, Garlanda C, Mantovani A. Unique pattern of expression and inhibition of IL-1 signaling by the IL-1 receptor family member TIR8/SIGIRR. Eur Cytokine Netw 2003, 14:211-218.
70. Drexler SK, Kong P, Inglis J, Williams RO, Garlanda C, Mantovani A, Yazdi AS, Brennan F, Feldmann M, Foxwell BM. SIGIRR/TIR-8 is an inhibitor of Toll-like receptor signaling in primary human cells and regulates inflammation in models of rheumatoid arthritis. Arthritis Rheum 2010, 62:2249-2261. 10.1002/art.27517, 20506350.
71. Xie P, Hostager BS, Munroe ME, Moore CR, Bishop GA. Cooperation between TNF receptor-associated factors 1 and 2 in CD40 signaling. J Immunol 2006, 176:5388-5400.
72. Tsitsikov EN, Laouini D, Dunn IF, Sannikova TY, Davidson L, Alt FW, Geha RS. TRAF1 is a negative regulator of TNF signaling. enhanced TNF signaling in TRAF1-deficient mice. Immunity 2001, 15:647-657. 10.1016/S1074-7613(01)00207-2, 11672546.
73. Song HY, Rothe M, Goeddel DV. The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-κB activation. Proc Natl Acad Sci USA 1996, 93:6721-6725. 10.1073/pnas.93.13.6721, 39093, 8692885.
74. Plenge RM, Seielstad M, Padyukov L, Lee AT, Remmers EF, Ding B, Liew A, Khalili H, Chandrasekaran A, Davies LR, Li W, Tan AK, Bonnard C, Ong RT, Thalamuthu A, Pettersson S, Liu C, Tian C, Chen WV, Carulli JP, Beckman EM, Altshuler D, Alfredsson L, Criswell LA, Amos CI, Seldin MF, Kastner DL, Klareskog L, Gregersen PK. TRAF1-C5 as a risk locus for rheumatoid arthritis - a genomewide study. N Engl J Med 2007, 357:1199-1209. 10.1056/NEJMoa073491, 2636867, 17804836.
75. Chang M, Rowland CM, Garcia VE, Schrodi SJ, Catanese JJ, van der Helm-van Mil AH, Ardlie KG, Amos CI, Criswell LA, Kastner DL, Gregersen PK, Kurreeman FA, Toes RE, Huizinga TW, Seldin MF, Begovich AB. A large-scale rheumatoid arthritis genetic study identifies association at chromosome 9q33.2. PLoS Genet 2008, 4:e1000107. 10.1371/journal.pgen.1000107, 2481282, 18648537.
76. Han TU, Bang SY, Kang C, Bae SC. TRAF1 polymorphisms associated with rheumatoid arthritis susceptibility in Asians and in Caucasians. Arthritis Rheum 2009, 60:2577-2584. 10.1002/art.24759, 19714643.
77. O'Connell RM, Rao DS, Chaudhuri AA, Baltimore D. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol 2010, 10:111-122. 10.1038/nri2708, 20098459.
78. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006, 103:12481-12486. 10.1073/pnas.0605298103, 1567904, 16885212.
79. O'Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA 2007, 104:1604-1609. 10.1073/pnas.0610731104, 1780072, 17242365.
80. Tili E, Michaille JJ, Cimino A, Costinean S, Dumitru CD, Adair B, Fabbri M, Alder H, Liu CG, Calin GA, Croce CM. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-α stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol 2007, 179:5082-5089.
81. Stanczyk J, Pedrioli DM, Brentano F, Sanchez-Pernaute O, Kolling C, Gay RE, Detmar M, Gay S, Kyburz D. Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum 2008, 58:1001-1009. 10.1002/art.23386, 18383392.
82. Nakasa T, Miyaki S, Okubo A, Hashimoto M, Nishida K, Ochi M, Asahara H. Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis Rheum 2008, 58:1284-1292. 10.1002/art.23429, 2749927, 18438844.
83. Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH, Chan EK. Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther 2008, 10:R101. 10.1186/ar2344, 2575615, 18759964.
84. Li J, Wan Y, Guo Q, Zou L, Zhang J, Fang Y, Fu X, Liu H, Lu L, Wu Y. Altered microRNA expression profi le with miR-146a upregulation in CD4+ T cells from patients with rheumatoid arthritis. Arthritis Res Ther 2010, 12:R81. 10.1186/ar3006, 2911863, 20459811.
85. Niimoto T, Nakasa T, Ishikawa M, Okuhara A, Izumi B, Deie M, Suzuki O, Adachi N, Ochi M. MicroRNA-146a expresses in interleukin-17 producing T cells in rheumatoid arthritis patients. BMC Musculoskelet Disord 2010, 11:209.
86. Chatzikyriakidou A, Voulgari PV, Georgiou I, Drosos AA. A polymorphism in the 3'-UTR of interleukin-1 receptor-associated kinase (IRAK1), a target gene of miR-146a, is associated with rheumatoid arthritis susceptibility. Joint Bone Spine 2010, 77:411-413. 10.1016/j.jbspin.2010.05.013, 20870441.
87. Thai TH, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y, Murphy A, Frendewey D, Valenzuela D, Kutok JL, Schmidt-Supprian M, Rajewsky N, Yancopoulos G, Rao A, Rajewsky K. Regulation of the germinal center response by microRNA-155. Science 2007, 316:604-608. 10.1126/science.1141229, 17463289.
88. Murata K, Yoshitomi H, Tanida S, Ishikawa M, Nishitani K, Ito H, Nakamura T. Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis. Arthritis Res Ther 2010, 12:R86. 10.1186/ar3013, 2911870, 20470394.
89. Nakamachi Y, Kawano S, Takenokuchi M, Nishimura K, Sakai Y, Chin T, Saura R, Kurosaka M, Kumagai S. MicroRNA-124a is a key regulator of proliferation and monocyte chemoattractant protein 1 secretion in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum 2009, 60:1294-1304. 10.1002/art.24475, 19404929.
90. Stanczyk J, Ospelt C, Karouzakis E, Filer A, Raza K, Kolling C, Gay R, Buckley CD, Tak PP, Gay S, Kyburz D. Altered expression of miR-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation. Arthritis Rheum 2011, 63:373-381. 10.1002/art.30115, 21279994.
91. Fulci V, Scappucci G, Sebastiani GD, Giannitti C, Franceschini D, Meloni F, Colombo T, Citarella F, Barnaba V, Minisola G, Galeazzi M, Macino G. miR-223 is overexpressed in T-lymphocytes of patients affected by rheumatoid arthritis. Hum Immunol 2010, 71:206-211. 10.1016/j.humimm.2009.11.008, 19931339.